๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Windward Bio Group AG (WWB)
null: WWB ยท Real-Time Price ยท USD
24.01
+1.37 (6.05%)
Nov 19, 2026, 4:00 PM EST - Market closed
โ† View all transcripts

Jefferies Global Healthcare Conference

Nov 18, 2026

Summary

WIN378 has advanced to phase III asthma testing, with phase II COPD dose-ranging ongoing and twice-yearly dosing as a key differentiator. WIN027 combines TSLP and IL-13 targeting, with global COPD and atopic dermatitis studies planned.

Operator

Good morning, ladies and gentlemen, and welcome to the 2026 Jefferies Healthcare Conference. It is now my pleasure to introduce Luca Santarelli, the CEO of Windward Bio. Just as a reminder, this will be a 20-minute presentation followed by about five minutes of Q&A.

Luca Santarelli
Founder and CEO, Windward Bio

Good morning, everyone, and thanks to Jefferies for having us present here. I am the Founder and CEO of Windward Bio, an I&I-focused company. I would like to tell you about our company, which was opened with an IPO on Friday last week. We are an immunology company focusing on COPD, asthma, atopic dermatitis. Our pipeline is concentrated on ultra-long-acting monoclonal antibodies that are targeting twice-yearly dosing and have improved potency. Our team is extremely experienced. We have been through other IPOs and trade sales. We also launched collectively more than 20 drugs. Our lead molecule is WIN378 in phase III for asthma currently, and had reported phase II data in September showing significant improvement in lung function and twice-yearly dosing regimen. We also have a bispecific molecule currently in phase II that is targeting TSLP and IL-13 with an extended half-life of 84 days.

Very good safety profile so far as seen in phase I studies recently reported. We expect to have approximately 10 clinical readouts between phase II and phase III over the next two and a half years. The focus of our pipeline is on targets that have significant level of validation from the clinic and have shown real potential to be best in disease. When it comes to TSLP, of course, we all know the data from TEZSPIRE in asthma and COPD, showing some of the best exacerbation reductions. When you look at IL-13, obviously we know about lebrikizumab, showing some of the best data in eosinophilic reduction across the class, all the classes of drugs. Of course, the combination of the two, we believe, has the potential to add additional efficacy both to respiratory and dermatological conditions. Here is the pipeline.

WIN378 is in phase III in asthma and in phase II in COPD. WIN027 is currently already in phase II in China in asthma, CRS, and atopic dermatitis. We are about to start global studies in COPD and atopic dermatitis. Both these molecules came from Chinese partners. We own global rights, they own China rights. We also have earlier-stage bispecifics , which are still pre-IND, and we will talk about those when we enter ILD. Here is the team. Many of us are here today. We were together in a previous company called VectivBio, which was public, and it was sold to Ironwood in 2023, and before that, a company called Therachon, both focusing on rare diseases, and Therachon was sold to Pfizer in 2019. The key focus of our approaches here is to improve the bar for, raise the bar for efficacy.

You see where the bar currently stands in asthma, COPD, and atopic dermatitis. The second main goal is to improve the treatment burden for patients by reducing the frequency of injections. Currently, biologics for these conditions require one or two injections a month, which amounts to a total of 26, 12 injections a year. We are planning to cut that down to about two injections a year. These are very large pool of patients. We are looking at 8 million biologic-eligible patients across these indications in the U.S., Europe, and Japan, adding up to the potential for a total market size of about $60 billion.

Okay, this market, importantly, is significantly under-penetrated to date. Part of it has to do with COPD, for example, drugs have only been recent in these indications, but part of it has to do with the fact that drugs are not sufficiently good or competitive at this point. The proposition for twice-yearly dosing is very clear. There is data originating from claims studies over the last two decades from the use of asthma biologic in asthma specifically that show that patients that start treatment, in 45% of cases are still on treatment 12 months, and 55% of cases stop treatment. So, discontinue because of a variety of reasons, but we believe the main reason is the complexity of treatment algorithm.

Those patients that discontinue have much higher rates of admission to hospital or emergency departments, which draws a close connection between the burden of treatment and poor treatment outcomes. We believe there are options out there that prove the fact that if you reduce treatment burden, you can have better persistency of use. Some examples of these are PROLIA, a drug that increases bone density in osteoporosis. For example, LEQVIO, that reduces cholesterol in cardiovascular disease.

These approach 80% persistency of use at 12 months, which is almost double the figure for asthma biologics. That is where we see the opportunity. Let us now switch over to our lead molecule, WIN378. This molecule has three key features that make it really competitive. One is the binding. The binding, it binds with high affinity to two separate sites on TSLP, and that makes the binding mode unique compared to other anti-TSLP agents.

We believe this endows the molecule with greater potency. Secondly, it has been Fc-engineered for longer-acting properties, with 75 days shown in human patients with asthma of half-life. Then we engineer also a LALA-G1 mutation, which eliminates effector function, that is the ability of the antibody to bind to immune cells, and that we think will lead to improved safety profiles, and we have seen some of that in the phase II results. We are able to manufacture this drug in the U.S. now. We have transferred the manufacturing out of China. Now, going back to the pharmacology, just a step back to explain here how TSLP signals. On the left side, you can see a picture of the receptor complex driving the signaling, made up of TSLP receptor in blue and IL-7 receptor alpha in orange.

The ligand binds to both receptors, stabilizes this conformation, and signals through this stabilized receptor complex. It does so with two interfaces, site one and site two. Tezepelumab, as many of the other anti-TSLP agents, including GSK's long-acting molecule, including Generate Biomedicines' long-acting molecule, all bind to the site one. Our molecule binds to both site one and site two. We believe that further destabilizes the signaling and increases the opportunity for the drug to be more potent. We have seen some of that evidence in preclinical studies, looking at human-derived PBMCs stimulated with TSLP, and in blocking that signal, our molecule showed a potency that was twice as high as tezepelumab. We have seen later in the data set that I will show you that this also translates to some additional potency in the clinic. Now, a look at our programs with WIN378.

We are currently engaged in two indications, asthma and COPD. Our asthma program is called POLARIS-1 and POLARIS-2. POLARIS-1 is a program that comprises two studies, a phase II dose ranging and a phase III pivotal. The phase II dose ranging has reported out interim results in September, which I will go over. We report out full results in the first half of next year, 24-week data and 48-week data around mid-year 2025. We have now started a phase III, POLARIS-1 phase III. We are about to start our second pivotal in Q1 2025. We are also running SIRIUS, which is a COPD phase II dose-ranging study, which will complete next year, and based on those results, we will select a dose for the phase III program in COPD. At the top line, the asthma phase II interim has shown three main aspects. First, the efficacy.

We observed significant and sustained improvement in lung function and inflammation, looking at FEV1 elevation, FeNO, and eosinophil reduction. We saw numerically greater improvement than previously reported with other drugs in the class. These effects were lining up with what we had predicted from preclinical experiments, and it sort of comforted our modeling approach. We also confirmed an half-life of 75 days and a persistency of efficacy at six months, which confirmed our twice-yearly dosing regimen. Lastly, and most importantly, the drug was well tolerated. We had zero treatment-related SAEs, no discontinuation related to adverse events, 0.7% injection site reaction, and just about 2% ADAs, so very, very low. Based on this, we have selected two doses and moved to phase III. The study design included four arms, one placebo arm and three active arms, 150, 300, and 600 milligram in a 3:1:1:3 randomization.

This was built this way to create a PK/PD model to establish the dose response to the best we could, using FeNO reduction as the primary PD parameter to establish dose selection for phase III. As I said, the very good safety profile, AE were balanced, and there were no treatment-related serious adverse events. For modeling the phase III, we used the MCP-Mod approach, which is basically an FDA-approved approach. We had a typical severe asthma population with an FE1 baseline of about 66%. A total of 165 patients were randomized. The data I will show you is the result of 96 patients achieving three months of exposure and about 55 patients achieving six months of exposure. First, the PK showed an half-life of up to 75 days and achievement of the 24-week target concentration that we had wanted for the top two doses.

Also, when we ran the PK/PD model and analysis, we were able to demonstrate an EC50 for FeNO reduction of 0.63 mcg/mL using the same modeling approach that was used by Amgen and AstraZeneca with TEZSPIRE. The published results with TEZSPIRE are reported below. You can see that their EC50 for FeNO reduction is 2.5 mcg/mL , which is fourfold higher. We are seeing here a translation of what we saw in the preclinical assays to the clinic in terms of the potency of the molecule in having a pharmacodynamic effect that is relevant in asthma. I want to remind you that FEV1 has been used by Amgen to validate and establish the dose response and the dose selection for TEZSPIRE. It is also highly correlated with exacerbation reduction. Even more important is lung function.

Lung function is measured by FEV1, showed a large sustained improvement above 300 and 600 mg. Those improvements are in line with the best-in-class efficacy here. And we were able, by this approach, to also eliminate one of the three dose levels, the 150, that showed no separation in these parameters. The effect is very rapid and is maintained. You can see the full effect at two weeks, about, and is maintained throughout the whole period. And if you compare those effects across the three doses and placebo, you can see that we see a placebo-adjusted reduction in FeNO, which is fairly sizable, pretty large, especially at the 600 mg and 300 mg dose. And if you look at FEV1, we are looking at 240 mL, or at 300 ML and 267 mL at 600.

This is in comparison with approximately 150 mL placebo-adjusted difference seen with TEZSPIRE in their phase IIb PATHWAY study, which has a similar population to ours. So very encouraged by these results, and now moving forward to the phase III program. The two programs, the two studies that make up the phase III Pivotal program are POLARIS-1 and POLARIS-2. POLARIS-1, they are basically very similar in size, 600 patients each. They still carry forward two doses, a high dose and a low dose. We are not testing any dose higher than 600. We are not disclosing exactly which doses these are based on our modeling. The key endpoints, of course, is annualized asthma exacerbation rate, and FEV1 is a key secondary on lung function. The primary analysis is expected 48 weeks, and we are expecting to have results in the first half of 2029.

For the COPD program, this is a study that is currently ongoing, SIRIUS, recruiting 105 patients across three dose levels. Main goal here is to establish a better dose response in this indication for choosing with more precision the dose to take to phase III. We will have results for this in the second half of next year. Last comment on why we believe our molecule is highly differentiating in the landscape of short and long-acting anti-TSLP agents. First, WIN378 is the only molecule to target both site one and site two, and as I have shown to you, we believe that gives the molecule greater opportunity to be more potent. It is the only long-acting product to have an Fc silencing approach, which leads to some of the best ADA and safety profiles. Only 3% ADAs across two studies, and injection site reaction less than 1%.

It is twice a year, so it addresses where we think the market is going to go in the future, and it reduces significantly treatment burden. Also, from an execution standpoint, we have disclosed one of the largest data sets in asthma this far from a long-acting agent. We are also already in phase III, so we are competitive on the timelines, and our COPD phase II is also ongoing. Our vision for the product is to be targeting best-in-disease efficacy across both asthma and COPD, beating those figures of 55% and 35% exacerbation reduction. For asthma, we are targeting all comers without restriction on eosinophil numbers. In COPD, we are focusing on the higher than 150 eosinophils. Now, switching over to our bispecific, WIN027. This is an ultra-long-acting molecule targeting both TSLP and IL-13.

Here, the logic was to target IL-13 and TSLP at the same time to benefit from the potential synergy. TSLP acting at the top of the inflammatory pathway and IL-13 being an effector cytokine down in the more cellular component of the pathway, the immune component of the pathway. The molecule that we have selected across a broad range of opportunities that we screened has three features, really. One is the very high affinity for both TSLP and IL-13 in the femtomolar range. Secondly is a YTE mutation that gives this molecule an 84-day half-life in human, based on phase I results, which we gathered in September. Lastly, it is built on an established platform which has multiple approved bispecifics, so it is a standard monoclonal with a very validated approach. Look at the affinity on the left side.

You can see that the KD, as measured by Biacore, is approximately 0.2 picomolar for TSLP and 0.7 for IL-13. That compares to larger figure for tezepelumab and lebrikizumab, approximately 64 higher affinity compared to teze and about six-fold higher affinity compared to lebri. This shows also on the potency assay on the right. This is done, again, in PBMCs. You can see that the teze-lebri combo is fully effective in blocking the TARC response, but WIN027 has a shift to the left, which indicates higher potency in this assay. The phase I results just came in, as I said, and they showed very good safety profile, low immunogenicity, approximately 3%, less than 5% injection site reaction, and a half-life of up to 84 days.

We are now moving, based on this result, this program into global studies in COPD and atopic dermatitis, initiating in beginning of next year, while our partner, Qyuns, has already started studies in AD, CRS, and asthma in China, with data expected somewhere between next year and the year after next. So we will have data next year, at least in AD from Qyuns, and also from an interim analysis on our study. Here, the vision is ambitious. We are looking to improve efficacy by a factor of 10%-15%, both in respiratory and COPD, and our first focus in atopic dermatitis. For respiratory, the initial focus is COPD. However, we are going to get data also from Qyuns, and we will assess whether there is merit to move also into asthma. In terms of the competitive comparisons, 027 has highly differentiated potency and half-life.

We're looking at a WIN378 potency and half-life of 84 days, with dosing potential of every six months. This compare favorably to the other couple of drugs in this class that we know of, one being Belenos Bio and the other one being J&J Proteologix. Obviously, longer acting than the drug we consider the best representative of this class this far, which is tilrekimig from Pfizer, that has shown some of the best data in atopic dermatitis.

In conclusion, we're expecting data from our phase II dose range finder, full data sets for six months, the first half of next year, 48 weeks, just the beginning of second half of next year. The second pivotal, POLARIS-2, will start soon, and is in launch phase. Then, we're expecting data from SIRIUS, second half of next year, and then potentially AD also next year. We have a lot of readouts in the next 12 months. The pivotal results from asthma POLARIS-1 are expected in first half of 2029. With that, I thank you. If there are questions. Okay. Thank you very much.